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Abstract Recently, a sequence encoding a novel mammalian
calcium-independent phospholipase A2 (iPLA2Q) was identi¢ed
in the human genome and subsequently cloned and expressed in
Sf9 insect cells. Unexpectedly, expression studies in recombi-
nant systems demonstrated the usage of multiple translation
initiation codons resulting in di¡erent polypeptides. Herein, we
demonstrate that hepatic iPLA2Q is localized to rat liver peroxi-
somes, possesses a molecular mass of 63 kDa and that peroxi-
somal membranes are highly enriched in arachidonic acid-con-
taining phospholipids. Collectively, these results provide the ¢rst
demonstration of iPLA2Q in mammalian tissue and suggest the
possibility that iPLA2Q can contribute to lipid second messenger
generation by hydrolysis of peroxisomal arachidonic acid-con-
taining phospholipids.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipases A2 are critical enzymes in cellular lipid me-
tabolism which regulate cellular energy storage, membrane
function and the generation of lipid second messengers [1,2].
Recently, we described the genomic organization, mRNA se-
quence and enzymatic activity of a novel calcium-independent
phospholipase A2 (i.e. iPLA2Q, (GenBank accession no.
AF263613)) [3]. Analysis of the message sequence of iPLA2Q
identi¢ed several potential translation initiation sites located
at residues 226, 526, 589 and 886, resulting in 88, 77, 74 and
63 kDa protein products, respectively [3]. Accordingly, we
cloned and expressed iPLA2Q in Sf9 cells utilizing a baculovi-
rus construct designed to drive the expression of the 88 kDa
isoform through usage of the ATG translation initiation co-
dons at residue 226. However, this construct failed to produce
the anticipated 88 kDa protein product and instead produced
protein products utilizing ATG translation initiation codons
at residues 526 and 886, resulting in 77 and 63 kDa polypep-
tides, respectively [3].
Sequence analysis demonstrated that iPLA2Q contained a
C-terminal peroxisomal localization sequence (-SKL) and
thus was predicted to be predominantly present in the peroxi-
somal compartment [3]. Peroxisomes ful¢ll a variety of lipid
anabolic and catabolic functions in eukaryotic cells [4^8].
Since phospholipases A2 catalyze the hydrolysis of a variety
of lipids, including phospholipids [9], lysophospholipids [10]
and acyl CoA derivatives [11], and thereby participate in the
regulation of lipid metabolic £ux and signaling, we reasoned
that iPLA2Q may regulate lipid metabolic £ux within the per-
oxisomal compartment. The present study was undertaken to
identify and characterize the iPLA2Q protein naturally occur-
ring in mammalian tissues. Speci¢cally, we sought to deter-
mine the isoforms of iPLA2Q expressed in mammalian tissues
(i.e. 88, 77, 74 or 63 kDa isoforms), con¢rm its anticipated
subcellular localization in the peroxisomal compartment and
gain insight into its potential physiological functions by anal-
ysis of peroxisomal membrane lipids using electrospray ion-
ization mass spectrometry (ESI-MS).
We now report that iPLA2Q predominantly exists as a 63
kDa polypeptide in rat liver and that the 63 kDa iPLA2Q
isoform predominantly localized to the peroxisomal compart-
ment. We further demonstrate that choline- and ethanoamine-
glycerophospholipids in hepatic peroxisomes contain a high
level of arachidonic acid-containing species. Collectively, the
demonstration of iPLA2Q in the peroxisomal compartment in
close spatial proximity to arachidonic acid-containing phos-
pholipids suggests a potential role for iPLA2Q in cellular lipid
homeostasis and lipid second messenger generation.
2. Materials and methods
2.1. Materials
Horseradish peroxidase (HRP)-linked protein A and ECL1 West-
ern blotting detection reagents were purchased from Amersham Bio-
tech (Piscataway, NJ, USA). Gelman acrodisc CR polytetra£uoro-
ethylene (PTFE) syringe ¢lters (0.2 Wm) were from Gelman Science
(Ann Arbor, MI, USA). BCA (bicinchoninic acid) protein assay kits
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were obtained from Pierce (Rockford, IL, USA). Antibodies against
PMP70, calnexin, and porin were from A⁄nity Bioreagents (Golden,
CO, USA), BD Transduction Laboratories (Lexington, KY, USA)
and Molecular Probes (Eugene, OR, USA), respectively. The antibody
against iPLA2Q was developed against peptide CENIPLDESR-
NEKLDQ and prepared as previously described [3]. The internal stan-
dards for ESI-MS were obtained from Avanti Polar Lipids (Alabaster,
AL, USA). Most other chemicals were from Sigma (St. Louis, MO,
USA). Sprague^Dawley rats used for these experiments were obtained
from Charles River Laboratory (Wilmington, MA, USA).
2.2. Isolation of peroxisomes
Peroxisomes were isolated from rat liver by di¡erential and density
gradient centrifugation [12]. Brie£y, 5 g of rat liver was homogenized
in three volumes (w/v) (15 ml) of homogenization bu¡er (0.25 M
sucrose, 5 mM MOPS, pH 7.4, 1 mM EDTA and 0.1% (v/v) of
ethanol, 0.2 mM dithiothreitol containing protease inhibitors (phen-
ylmethylsulfonyl £uoride (0.2 mM), leupeptin (1 Wg/ml), aprotinin
(1 Wg/ml) and phosphoramidon (15 Wg/ml)). Liver was cut into pieces
and homogenized at 1000 rpm with a single stroke using a Potter-
Elvehjem homogenizer. The homogenate was centrifuged at 100Ug
for 10 min to remove cellular debris. The pellet was re-homogenized
and again centrifuged at 100Ug for 10 min. The supernatants were
combined and centrifuged at 1000Ug for 10 min. The resultant pellet
was resuspended in homogenization bu¡er and centrifuged similarly.
The pellet was used as the nuclear fraction. The combined superna-
tants were pooled and centrifuged at 3000Ug for 20 min to produce
the heavy mitochondrial fraction. The supernatant was centrifuged at
25 300Ug to pellet a light mitochondrial fraction. The pellet was re-
suspended in homogenization bu¡er and again centrifuged at
25 300Ug for 15 min. The supernatant of 25 300Ug was centrifuged
at 100 000Ug to produce a microsomal pellet and cytosolic fraction.
The light mitochondrial pellet was resuspended in 2.5 ml of homog-
enization bu¡er. The resuspension was layered on top of a discontin-
uous Nycodenz gradient (2 ml of 56% (w/v), 4 ml of 45% (w/v) and 16
ml of 30% (w/v) Nycodenz) prepared in the gradient bu¡er (homog-
enization bu¡er without sucrose). After centrifugation at 35 000Ug
for 1 h, the peroxisomal fraction present at the interface between
the 30% and 45% Nycodenz layers was aspirated and used for sub-
sequent experiments.
2.3. Western blotting
The relative enrichment and degree of contamination of the peroxi-
somal fraction was determined by comparing the intensity of marker
proteins from di¡erent organelles by Western blot analysis. Proteins
were separated by 10% sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) [13] and transferred to Immobilon-P
membranes in 10 mM CAPS bu¡er (pH 11) containing 10% methanol.
Powdered milk (5% (w/v)) was used to block the non-speci¢c binding
sites prior to incubation with primary antibody. HRP-linked second-
ary antibodies or HRP-linked protein A were used in combination
with an ECL detection system to visualize immunoreactive bands.
2.4. Phospholipid extraction
Phospholipids were extracted from isolated peroxisomes by a modi-
¢ed method of Bligh and Dyer [14]. Internal standards including 14:1-
14:1 PtdCho (phosphatidylcholine; 40 nmol/mg protein), 15:0-15:0
PtdEtn (phosphatidylethanolamine; 25 nmol/mg protein) and 14:0-
16:0 phosphatidylglycerol (6 nmol/mg protein) were added to the
chloroform extract for quantitation of choline-containing, ethanol-
amine-containing and anionic phospholipids, respectively [15,16].
The lipid extracts were dried under a nitrogen stream, dissolved in
chloroform, ¢ltered with PTFE syringe ¢lters and dried again under a
N2 stream. The ¢nal lipid residue was resuspended in 0.2 ml of 1:1
chloroform/methanol prior to ESI-MS analysis.
2.5. ESI-MS of phospholipids
ESI-MS analyses were performed on a Finnigan TSQ-7000 spec-
trometer equipped with an electrospray ion source, as previously de-
scribed [16,17]. Diluted samples were infused into the ESI source at
the £ow rate of 1 Wl/min with a Harvard syringe pump. Anionic phos-
pholipids were quantitated in the negative ion mode by comparison
with the internal standards. After rendering the solution basic with
LiOH in methanol (50 nmol/mg of protein), ethanolamine glycero-
phospholipids were quantitatively analyzed in the negative-ion mode,
and choline glycerophospholipids were quanti¢ed as their lithium ad-
ducts in the positive-ion mode by comparisons with internal stan-
dards. Data were corrected for the 13C isotope e¡ects as previously
described [18].
2.6. Protein assay
Protein concentration was determined utilizing a BCA protein assay
kit using bovine serum albumin as standard according to the manu-
facturer’s instruction.
3. Results
3.1. Characterization of peroxisomes
Since Northern analysis of mammalian tissues identi¢ed the
presence of iPLA2Q message in multiple tissues, including
heart, brain, liver, and pancreas [3], we initially attempted
to identify the molecular mass(es) of the expressed polypep-
tides from Western blot analysis of the membrane fractions
derived from these tissues. However, no immunoreactive
bands could be visualized in crude membrane preparations
due to the low abundance of iPLA2Q. Accordingly, we puri¢ed
rat hepatic peroxisomes by established procedures (i.e. Nyco-
denz discontinuous gradient centrifugation) [12]. To determine
the purity of the peroxisomal preparation, Western blot anal-
yses were performed to demonstrate the relative enrichment of
peroxisomes and degree of cross contamination by other sub-
cellular organelles using antibodies against the subcellular
markers PMP70 (peroxisomes) [19,20], porin (mitochondria)
[21] and calnexin (endoplasmic reticulum) [22,23] (Fig. 1). The
high intensity of PMP70 and the corresponding relatively low
intensities of calnexin and porin in the peroxisomal fraction
indicated that highly puri¢ed peroxisomes were obtained and
used in our studies (Fig. 1).
3.2. Detection of iPLA2Q in mammalian peroxisomes
To determine the subcellular localization of iPLA2Q and to
identify the molecular mass(es) of its isoforms in mammalian
tissues, proteins of each fraction were separated by SDS^
PAGE and analyzed by Western blotting. Probing with anti-
body directed against the iPLA2Q peptide CENIPLDESR-
NEKLDQ (735^750) [3] demonstrated that a 63 kDa protein
was present in the isolated rat liver peroxisomes (Fig. 2) with
no observable signal in the other fractions. This represents the
¢rst identi¢cation of the mass of naturally occurring iPLA2Q
Fig. 1. Demonstration of the purity of isolated peroxisomes. Equal
amounts of protein (20 Wg) from rat liver homogenate (HM), nuclei
(NF), mitochondria (MITO), microsomes (MICRO), cytosol (CYT),
light mitochondrial fraction (LMF) and peroxisomes (PERO) were
separated by SDS^PAGE, transferred to Immobilon-P membranes,
probed with antibodies against PMP70, porin and calnexin, and vi-
sualized by enhanced chemiluminescence detection.
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(i.e. that present in non-recombinant systems) and the ¢rst
demonstration that iPLA2Q is localized in the peroxisomal
compartment.
3.3. ESI-MS analysis of phospholipid molecular species in rat
liver peroxisomes
Lipid extracts from rat liver peroxisomes were quantita-
tively analyzed by ESI-MS and ESI tandem mass spectrome-
try (MS/MS) as previously described [16,17]. The presence of
phosphatidylserine (PtdSer) molecular species was veri¢ed by
identifying the neutral loss of 87 in the negative-ion mode,
and peaks corresponding to phosphatidylinositol (PtdIns)
were veri¢ed by the product ion of m/z 241 in the negative-
ion mode (data not shown). Choline containing lipids (Ptd-
Cho and sphingomyelin) were veri¢ed by MS/MS through
demonstrating the neutral loss of 183 in the positive-ion
mode (Fig. 3). Quantitation of each phospholipid class was
accomplished by comparisons with internal standards. As
summarized in Table 1, puri¢ed peroxisomes contain 105
nmol of phospholipid/mg protein. The predominant phospho-
lipid classes are choline-(PtdCho) and ethanolamine-contain-
ing (PtdEth) glycerophospholipids. PtdCho is the most abun-
dant class, representing 60% of the total phospholipids.
PtdEth represents 38% of total phospholipids. Thus PtdCho
and PtdEth collectively constituteV98% of the phospholipids
in hepatic peroxisomes. The low anionic phospholipid content
of peroxisomes (2%) is quite unusual amongst intracellular
membrane fractions we and others have examined [16,24].
Moreover, detectable amounts of ether lipids were not ob-
served. No detectable sphingomyelin or cardiolipin was ob-
served, attesting to the low plasma membrane or mitochon-
drial contamination in the peroxisomal preparations utilized
and further underscoring its purity [25]. The predominant
molecular species of PtdCho and PtdEth were quite similar,
which is also unusual for most mammalian membrane frac-
tions we have examined [16,24]. The presence of highly unsat-
urated fatty acids (i.e. arachidonic acid and cervonic acid) was
observed in both classes. The dominant PtdCho molecular
species are 18:0-20:4, 16:0-20:4 and 18:1-20:4, accounting
for 66% of the total choline-containing phospholipids (Fig.
3 and Table 1). No disaturated fatty acid-containing species
were observed in any of the phospholipid classes. PtdIns was
the major anionic phospholipid species present and 18:0-20:4
PtdIns was the only detectable molecular species present.
4. Discussion
The initial insights leading to the identi¢cation of a second
calcium-independent phospholipase A2 (i.e. iPLA2Q) in mam-
malian tissues were gleaned from the sequencing of the human
genome which identi¢ed a lipase consensus sequence present
on chromosome 7. Analysis of 5P and 3P neighboring sequen-
ces provisionally identi¢ed a 40 kDa protein product spanning
from physical markers 79 671 to 109 912 on chromosome 7.
Fig. 2. Characterization of iPLA2Q by Western blotting. Equal
amounts of proteins (20 Wg) from individual subcellular fractions
were loaded onto SDS polyacrylamide gel, electrophoresed and
transferred to Immobilon-P membranes. The blot was probed with
the antibody directed against iPLA2Q, demonstrating a robust signal
which co-puri¢ed with the peroxisomal marker PMP70.
Fig. 3. Positive-ion EIS-MS/MS spectra of choline glycerophospholi-
pids in lipid extracts of rat liver peroxisomal fraction. Lipid extracts
were prepared and analyzed in the positive-ion mode by ESI-MS/
MS employing the neutral loss of 183 as described in Section 2. The
internal standard is 14:1-14:1 PtdCho (m/z of [M+Li]þ is 681).
Lithiated PtdCho molecular species were identi¢ed by product-ion
ESI-MS and are tabulated in Table 1.
Table 1
Phospholipid content of rat liver peroxisomes
PtdCho nmol/mg protein mol% PtdEtn nmol/mg protein mol% Anionic
phospholipids
nmol/mg protein mol%
16:0-18:1 5.09T 1.00 4.8 16:1-18:1 4.16T 0.88 4.0 PtdSer
16:0-20:4 19.18T 4.00 18.3 16:0-20:4 5.57T 0.62 5.3 18:1-22:6 0.60T 0.06 0.6
18:1-18:1/18:0-18:2 3.49T 0.26 3.3 18:1-18:1/18:0-18:2 2.92T 0.25 2.8
16:0-22:6 8.88T 1.50 8.5 16:0-22:6 7.02T 1.25 6.7 PtdIns
18:1-20:4 7.10T 1.00 6.8 18:1-20:4 5.40T 1.21 5.1 18:0-20:4 1.50T 0.33 1.4
18:0-20:4 15.54T 1.80 14.8 18:0-20:4 9.72T 1.88 9.3
18:0-22:6 4.07T 0.40 3.9 18:0-22:6 4.72T 0.38 4.5
Total 63.35 60.4 Total 39.51 37.6 Total 2.10 2.0
Lipids were extracted from rat liver peroxisomes and quantitatively analyzed by ESI-MS as described in Section 2. Results are reported as the
meanTS.E.M. The ¢rst number in each pair refers to the number of carbon atoms in the fatty acid chain. The number after the colon refers
to the number of double bonds.
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Based on those initial insights, we identi¢ed the predicted
complete amino acid sequence of iPLA2Q [3]. Accordingly,
we constructed a baculovirus expression vector designed for
the expression of a predicted 88 kDa protein product. Re-
markably, infection of Sf9 cells with this vector led to the
production of V77 and 63 kDa protein products with no
evidence for the predicted 88 kDa polypeptide [3]. However,
naturally occurring (i.e. non-recombinant) iPLA2Q protein has
not previously been identi¢ed and thus the types of iPLA2Q
translated in mammalian cells were not known. In the present
study, we demonstrated for the ¢rst time that iPLA2Q is
present in rat liver peroxisomes and possesses a molecular
weight of 63 kDa. The localization of iPLA2Q to the peroxi-
somal compartment was not unanticipated because iPLA2Q
contains a C-terminal SKL peroxisomal targeting sequence
[3].
The functional role of iPLA2Q in peroxisomal lipid metab-
olism is unknown at present. Since the directed regulation of
the £ux of fatty acids in the peroxisomal compartment into
either lipid oxidative or synthetic pathways seems essential to
cellular energy storage and utilization [4^8], the enzymes that
direct the £ow of these metabolites into anabolic or catabolic
pathways are candidate enzymes for regulatory determinants
of obesity. Considering the signi¢cant roles which phospholi-
pases A2 play in cellular function in many systems [1,2] and
the localization of iPLA2Q to the peroxisomal fraction, we
propose that iPLA2Q may participate in the regulation of cel-
lular energy storage and utilization. Indeed, Hajra et al. dem-
onstrated that approximately half of cellular triacylglycerides
originated through initial lipid anabolic synthetic steps in the
peroxisomal compartment [8]. Thus, it seems likely that the 63
kDa iPLA2Q isoform contributes to and regulates the £ux of
aliphatic chains into cellular triacylglycerol pools.
Having puri¢ed peroxisomes in hand, we exploited recent
advances in ESI-MS to gain insight into the potential roles of
iPLA2Q function in mammalian tissues from the molecular
species analysis of peroxisomal membrane lipids. The results
of ESI-MS analysis were remarkable for the high content of
choline glycerolphospholipids containing arachidonic acid in
peroxisomal membranes. Approximately 66% of peroxisomal
choline glycerophospholipids contained arachidonic acid,
which is higher than that from multiple other subcellular frac-
tions we have analyzed [16,24]. Since recombinant iPLA2Q
actively catalyzes the hydrolysis of arachidonic acid-contain-
ing choline glycerophospholipids at the sn-2 position [3], and
those lipids are in close spatial juxtaposition to iPLA2Q, this
raises the intriguing possibility that peroxisomal membranes
represent a potential source for arachidonic acid released dur-
ing cellular perturbations. Thus, iPLA2Q is also a candidate
enzyme potentially contributing to the production of biolog-
ically active eicosanoids. The recent identi¢cation of chiral
mechanism-based inhibitors which discriminate iPLA2L activ-
ity from iPLA2Q activity can thus be utilized to assess the
role(s) of each enzyme in cellular lipid metabolism [26]. Fi-
nally, the mechanisms through which lipid precursors origi-
nating in the peroxisomal compartment are tra⁄cked to their
subsequent intracellular destinations has not been de¢ned.
Since no ESI-MS evidence for the accumulation of lysophos-
phatidic acid, alkyl-DHAP or alkyl glycerophosphates were
observed, the present results are consistent with the notion
that peroxisomal lipid synthetic precursors are transported
(either actively or passively) to their sites of ¢nal lipid cova-
lent assembly faster than they accumulate in the peroxisomal
membrane [8].
In summary, the present study identi¢es iPLA2Q in rat liver
as a 63 kDa protein product, demonstrates the predominant
peroxisomal localization of this polypeptide and identi¢es ar-
achidonic acid-containing choline glycerophospholipids in
close spatial proximity to iPLA2Q, thereby rendering this
pool a potential contributor to eicosanoid release in mamma-
lian cells after stimulation.
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